Defense Stocks Surge as Golden Dome Missile Tests Reshape Market Expectations

SpaceX, Northrop Grumman and Lockheed Martin just passed a critical round of orbital interceptor tests for the U.S. Golden Dome missile defense program, according to Investor's Business Daily. It's the kind of milestone that rearranges contract pipelines — and, more importantly, the kind that moves analyst desks before the contracts are even written. Business Day's market roundup touched on the broader tape midweek, but the real signal was buried in the defense names.

The Golden Dome Bid

The Space Force confirmed the tests this week. Citi, predictably, moved on Thursday — revising its price targets upward on the contractors it likes. Read that sequence carefully. A bulge-bracket desk doesn't get aggressive on defense primes unless somebody already knows the appropriations train has left the station. The awards haven't been finalized. The multiples are already getting bid.

So what's a portfolio to do? If you own the primes, you're along for the ride. If you've been waiting for a dip — good luck. Watch the second-tier names feeding the primes; they tend to follow, and the multiple expansion hits them harder when it arrives.

The Tape Around It

Two other threads from this week's coverage deserve a footnote. Business Standard flagged that FMCG shares dropped for a second consecutive session — not exactly a bull case for consumer staples, but a reminder that the rotation out of defensives is real, not theoretical. Hürriyet Daily News noted that companies are still rushing to IPO even as investors grow more cautious about pricing them. Translation: bankers want their fees, and buyers have finally learned what happens when you chase a deal just because the syndicate is hot.

The pattern is the same one I watched in 2008, by the way. Capital markets stay open long past the point where they should. Issuers keep tapping the window because it's open. The marginal buyer disappears quietly, and the next thing you know, a "consensus" IPO is down sharply six months later.

What I'm Watching

Golden Dome contract awards. FMCG volume into the back half of August — if those names keep bleeding, the rotation thesis has legs. And the IPO calendar: watch the spread between deal price and first-day pop. When that compresses, the cycle is closer to its end than its middle.

The tape doesn't lie. It just requires a translator. And right now, the translator is telling you that defense is the trade, consumer staples are a fading safe haven, and the IPO window is running on fumes.